298 related articles for article (PubMed ID: 30106121)
1. CIP2A depletion potentiates the chemosensitivity of cisplatin by inducing increased apoptosis in bladder cancer cells.
Gao F; Wang X; Chen S; Xu T; Wang X; Shen Y; Dong F; Zhong S; Shen Z
Oncol Rep; 2018 Nov; 40(5):2445-2454. PubMed ID: 30106121
[TBL] [Abstract][Full Text] [Related]
2. Increase in CIP2A expression is associated with cisplatin chemoresistance in gastric cancer.
Ji J; Zhen W; Si Y; Ma W; Zheng L; Li C; Zhang Y; Qin S; Zhang T; Liu P; Zheng X; Liu Y
Cancer Biomark; 2018 Feb; 21(2):307-316. PubMed ID: 29103022
[TBL] [Abstract][Full Text] [Related]
3. CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells.
Chen KF; Liu CY; Lin YC; Yu HC; Liu TH; Hou DR; Chen PJ; Cheng AL
Oncogene; 2010 Nov; 29(47):6257-66. PubMed ID: 20729919
[TBL] [Abstract][Full Text] [Related]
4. [Ethoxysanguinarine directly targets CIP2A to inhibit proliferation and induce autophagy of SGC7901/DDP cells].
Wan F; Tan M; Xiang YC; Liu XW; Peng P; Liu Y
Zhongguo Zhong Yao Za Zhi; 2022 Nov; 47(21):5890-5899. PubMed ID: 36472008
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize NSCLC cells to cisplatin.
Wei L; Qu W; Sun J; Wang X; Lv L; Xie L; Song X
Cancer Gene Ther; 2014 May; 21(5):194-9. PubMed ID: 24874844
[TBL] [Abstract][Full Text] [Related]
6. CIP2A is a target of bortezomib in human triple negative breast cancer cells.
Tseng LM; Liu CY; Chang KC; Chu PY; Shiau CW; Chen KF
Breast Cancer Res; 2012 Apr; 14(2):R68. PubMed ID: 22537901
[TBL] [Abstract][Full Text] [Related]
7. Polyphyllin I inhibits growth and invasion of cisplatin-resistant gastric cancer cells by partially inhibiting CIP2A/PP2A/Akt signaling axis.
Zhang Y; Huang P; Liu X; Xiang Y; Zhang T; Wu Y; Xu J; Sun Z; Zhen W; Zhang L; Si Y; Liu Y
J Pharmacol Sci; 2018 Jul; 137(3):305-312. PubMed ID: 30119963
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen induces apoptosis through cancerous inhibitor of protein phosphatase 2A-dependent phospho-Akt inactivation in estrogen receptor-negative human breast cancer cells.
Liu CY; Hung MH; Wang DS; Chu PY; Su JC; Teng TH; Huang CT; Chao TT; Wang CY; Shiau CW; Tseng LM; Chen KF
Breast Cancer Res; 2014 Sep; 16(5):431. PubMed ID: 25228280
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of CIP2A determines erlotinib-induced apoptosis in hepatocellular carcinoma.
Yu HC; Chen HJ; Chang YL; Liu CY; Shiau CW; Cheng AL; Chen KF
Biochem Pharmacol; 2013 Feb; 85(3):356-66. PubMed ID: 23178652
[TBL] [Abstract][Full Text] [Related]
10. CIP2A mediates fibronectin-induced bladder cancer cell proliferation by stabilizing β-catenin.
Gao F; Xu T; Wang X; Zhong S; Chen S; Zhang M; Zhang X; Shen Y; Wang X; Xu C; Shen Z
J Exp Clin Cancer Res; 2017 May; 36(1):70. PubMed ID: 28521777
[TBL] [Abstract][Full Text] [Related]
11. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
[TBL] [Abstract][Full Text] [Related]
12. Cucurbitacin B induces autophagy and apoptosis by suppressing CIP2A/PP2A/mTORC1 signaling axis in human cisplatin resistant gastric cancer cells.
Liu X; Duan C; Ji J; Zhang T; Yuan X; Zhang Y; Ma W; Yang J; Yang L; Jiang Z; Yu H; Liu Y
Oncol Rep; 2017 Jul; 38(1):271-278. PubMed ID: 28534965
[TBL] [Abstract][Full Text] [Related]
13. CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation.
Wang CY; Chao TT; Chang FY; Chen YL; Tsai YT; Lin HI; Huang YC; Shiau CW; Yu CJ; Chen KF
Lung Cancer; 2014 Aug; 85(2):152-60. PubMed ID: 24954871
[TBL] [Abstract][Full Text] [Related]
14. Role of CIP2A in the antitumor effect of bortezomib in colon cancer.
Ding Y; Wang Y; Ju S; Wu X; Zhu W; Shi F; Mao L
Mol Med Rep; 2014 Jul; 10(1):387-92. PubMed ID: 24789441
[TBL] [Abstract][Full Text] [Related]
15. Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism.
Wang HW; Yang SH; Huang GD; Lin JK; Chen WS; Jiang JK; Lan YT; Lin CC; Hwang WL; Tzeng CH; Li AF; Yen CC; Teng HW
J Cancer Res Clin Oncol; 2014 Apr; 140(4):561-71. PubMed ID: 24493623
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of polyphyllins I and VII on human cisplatin-resistant NSCLC via p53 upregulation and CIP2A/AKT/mTOR signaling axis inhibition.
Feng FF; Cheng P; Sun C; Wang H; Wang W
Chin J Nat Med; 2019 Oct; 17(10):768-777. PubMed ID: 31703757
[TBL] [Abstract][Full Text] [Related]
17. Effects of VBMDMP on the reversal of cisplatin resistance in human lung cancer A549/DDP cells.
Wang CK; Zhang Y; Zhang ZJ; Qiu QW; Cao JG; He ZM
Oncol Rep; 2015 Jan; 33(1):372-82. PubMed ID: 25394854
[TBL] [Abstract][Full Text] [Related]
18. Arctigenin inhibits triple-negative breast cancers by targeting CIP2A to reactivate protein phosphatase 2A.
Huang Q; Qin S; Yuan X; Zhang L; Ji J; Liu X; Ma W; Zhang Y; Liu P; Sun Z; Zhang J; Liu Y
Oncol Rep; 2017 Jul; 38(1):598-606. PubMed ID: 28560452
[TBL] [Abstract][Full Text] [Related]
19. Expression and biological role of CIP2A in human astrocytoma.
Yi F; Ni W; Liu W; Bai J; Li W
Mol Med Rep; 2013 May; 7(5):1376-80. PubMed ID: 23467938
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of cancerous inhibitor of protein phosphatase 2A may sensitize metastatic castration-resistant prostate cancer cells to cabazitaxel chemotherapy.
Huang J; Jia J; Tong Q; Liu J; Qiu J; Sun R; Yao L; Yang C
Tumour Biol; 2015 Mar; 36(3):1589-94. PubMed ID: 25377160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
